Analysts Set Xencor, Inc. (NASDAQ:XNCR) PT at $29.50

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has earned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $29.50.

A number of research firms have weighed in on XNCR. Wedbush reaffirmed an "outperform" rating and set a $31.00 target price on shares of Xencor in a report on Wednesday, April 30th. Wells Fargo & Company cut their price objective on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Barclays cut their price objective on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Finally, William Blair started coverage on Xencor in a report on Monday, April 21st. They set an "outperform" rating for the company.

Xencor Price Performance

XNCR stock remained flat at $8.06 during mid-day trading on Wednesday. The company's stock had a trading volume of 728,954 shares, compared to its average volume of 646,631. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $573.64 million, a P/E ratio of -2.52 and a beta of 0.99. Xencor has a 1-year low of $7.16 and a 1-year high of $27.24. The company has a 50-day moving average price of $10.08 and a two-hundred day moving average price of $17.06.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). The company had revenue of $32.73 million for the quarter, compared to analysts' expectations of $23.44 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm's quarterly revenue was up 104.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.11) EPS. As a group, analysts forecast that Xencor will post -3.68 EPS for the current year.

Insider Buying and Selling

In related news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the sale, the executive vice president now owns 49,169 shares in the company, valued at $542,334.07. The trade was a 8.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.76% of the stock is currently owned by corporate insiders.

Institutional Trading of Xencor

Hedge funds have recently bought and sold shares of the company. Barclays PLC lifted its position in Xencor by 100.7% in the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after purchasing an additional 78,066 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Xencor by 2.9% in the third quarter. JPMorgan Chase & Co. now owns 130,354 shares of the biopharmaceutical company's stock valued at $2,621,000 after purchasing an additional 3,635 shares during the last quarter. GAMMA Investing LLC lifted its position in Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 508 shares during the last quarter. KBC Group NV lifted its position in Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 813 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Xencor by 24.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,839 shares of the biopharmaceutical company's stock valued at $341,000 after acquiring an additional 2,946 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.